Cesca Therapeutics Inc. Announces Release of X-Mini™ Cell …GlobeNewswire (press release)RANCHO CORDOVA, Calif., April 03, 2018 (GLOBE NEWSWIRE) — Cesca Therapeutics Inc. (“Cesca”) (NASDAQ:KOOL), a market leader in automated cell processing and point… Continue reading
KFGOPfizer signs deal with Allogene to develop cancer cell therapyKFGO(Reuters) – Pfizer Inc said on Tuesday it signed an agreement with Allogene Therapeutics, a company formed by a consortium in which the drugmaker will hold a 25 percent stake, to fur… Continue reading
NasdaqCellectis, Allogene To Continue Strategic Cancer Immunotherapy CollaborationNasdaq(RTTNews.com) – Cellectis ( CLLS ) and Allogene Therapeutics Inc. said that Allogene intends to assume from Pfizer the global strategic collaboration to develop &qu… Continue reading
South China Morning PostHong Kong beauty salon blunders spark move to regulate stem cell treatment and therapiesSouth China Morning PostThe Hong Kong government on Tuesday moved a step closer to regulating stem cell treatment and other “advanced therap… Continue reading
Pfizer and Allogene Therapeutics Enter into Asset Contribution …Digital Journalannounced that the two companies have entered into an asset contribution.and more »… Continue reading
Drug Discovery & DevelopmentCombination Immunotherapy Improves Survival in Mouse Models of MesotheliomaDrug Discovery & DevelopmentCombined treatment with two cancer immunotherapy drugs – one a novel immune modulator and one that focuses and activates … Continue reading
Pfizer signs deal with Allogene to develop cancer cell therapyReutersSan Francisco-based Allogene specializes in cancer treatment by developing CAR T cell therapy for blood cancer and tumors. Servier and Allogene aim to start mid-stage studies in 2019 … Continue reading
Business Wire (press release)Cellectis and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate …Business Wire (press release)Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS – Nasdaq: CLLS)… Continue reading